کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2137693 | 1087856 | 2010 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN™), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of ≤30 mg/day. The most common adverse events were diarrhea, hypertension and fatigue. Six patients experienced an objective response (3 each at 20 and 30 mg). Dose- and time-dependent reductions in sVEGFR-2 were observed, and there was a positive correlation between cediranib exposure and the change in plasma VEGF levels from baseline. Cediranib was generally well tolerated and showed preliminary evidence of activity as a monotherapy.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 34, Issue 2, February 2010, Pages 196–202
Journal: Leukemia Research - Volume 34, Issue 2, February 2010, Pages 196–202
نویسندگان
Walter Fiedler, Rolf Mesters, Michael Heuser, Gerhard Ehninger, Wolfgang E. Berdel, Ute Zirrgiebel, Jane D. Robertson, Tom A. Puchalski, Barbara Collins, Juliane M. Jürgensmeier, Hubert Serve,